Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump

Eli Lilly raised its full-year revenue forecast to $91B-$92B, up from $85B-$87B, driven by strong demand for its weight-loss drugs Mounjaro and Zepbound. Third-quarter revenue was $24.4B, beating estimates, while adjusted profit per share also exceeded expectations. Foundayo, a newer obesity pill, underperformed but saw strong US demand. Shares rose 8% following the news.

Original reporting
Published Oct 29, 2026, 10:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump — source image
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The company’s raised revenue forecast and Q3 beat are immediate positives, but the Foundayo sales miss and price erosion details keep the competitive and margin debate active.

02

Market read

This is a same-day earnings-and-guidance catalyst for LLY, with the market balancing stronger topline outlook against a specific product ramp concern.

03

What to watch

The CFO attributes Foundayo shortfall to channel stocking and cites inventory effects; traders may need to watch subsequent quarters for whether demand sustains after the launch-quarter pull-forward.

Relevance 9/10Novelty 9/10Timing: early trading reaction to raised full-year revenue outlook

Background

Lilly is competing in the GLP-1 obesity market against Novo Nordisk, with investors tracking both injectable demand (Mounjaro, Zepbound) and the oral obesity pill Foundayo ramp.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly raised full-year revenue guidance to $91B-$92B and beat Q3 profit as weight-loss demand offset a weaker Foundayo launch.

Expected impact

Likely upward bias as the market reprices revenue expectations higher, partially offset by lingering concerns about Foundayo ramp.

Evidence & confidence

The article reports a specific guidance increase versus prior forecast, a Q3 revenue/EPS beat, and a concrete Foundayo sales shortfall that investors are actively monitoring.

Market effects

Reinforces GLP-1 leadership narrative and may intensify read-through competition expectations across the obesity drug class.

US large-cap biotech sentiment likely supported by the same-day guidance beat.

Competitive dynamics with Novo Nordisk remain central, influencing global GLP-1 supply and pricing expectations.

Counterpoint

The Foundayo miss and realized price declines (including US price pressure tied to Zepbound) suggest margin risk could re-emerge even with higher revenue guidance.

Key entities

  • Eli Lilly

    Raised full-year revenue outlook and reported Q3 beat; Foundayo sales lagged estimates.

  • Novo Nordisk

    Named as Danish rival whose first-mover edge investors compare against Lilly’s oral Foundayo.

  • Foundayo

    Lilly’s newer obesity pill; Q3 sales came in below estimates and is a key ramp test.

  • Mounjaro

    Diabetes drug whose Q3 sales growth helped offset Foundayo weakness.

  • Zepbound

    Obesity injection; Q3 sales beat estimates.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.